JP2024527974A5 - - Google Patents
Info
- Publication number
- JP2024527974A5 JP2024527974A5 JP2024504984A JP2024504984A JP2024527974A5 JP 2024527974 A5 JP2024527974 A5 JP 2024527974A5 JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024527974 A5 JP2024527974 A5 JP 2024527974A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110897167.2 | 2021-08-05 | ||
| CN202110897167 | 2021-08-05 | ||
| PCT/CN2022/110539 WO2023011631A1 (zh) | 2021-08-05 | 2022-08-05 | 治疗小细胞肺癌的药物组合 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527974A JP2024527974A (ja) | 2024-07-26 |
| JP2024527974A5 true JP2024527974A5 (cg-RX-API-DMAC7.html) | 2025-08-13 |
Family
ID=85154833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504984A Pending JP2024527974A (ja) | 2021-08-05 | 2022-08-05 | 小細胞肺がんを治療する薬物の組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240343807A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4382123A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527974A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240046526A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116209443A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022321783A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227992A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023011631A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118267468A (zh) * | 2019-01-25 | 2024-07-02 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物组合物 |
| WO2024155790A2 (en) * | 2023-01-18 | 2024-07-25 | Onkosxcel Therapeutics, Llc | Novel approach for treatment of cancer using immunomodulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201901057UA (en) * | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| CN116077647B (zh) * | 2018-07-18 | 2025-06-27 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| SG11202102682SA (en) * | 2018-09-18 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Quinoline derivative used for treating small cell lung cancer |
| CN111617243B (zh) * | 2019-02-28 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| BR112021017678A2 (pt) * | 2019-03-07 | 2021-11-16 | Advenchen Pharmaceuticals Llc | Uso de catequentinibe (anlotinibe) combinando com quimioterapia padrão ou imunoterapia em ordem sequencial para o tratamento de câncer |
| CN113613674B (zh) * | 2019-03-15 | 2024-11-05 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的联用药物组合物 |
| JP7761490B2 (ja) * | 2019-05-20 | 2025-10-30 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 小細胞肺がんの併用療法用キノリン誘導体 |
| WO2020249018A1 (zh) * | 2019-06-10 | 2020-12-17 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗驱动基因阳性肺癌的联用药物组合物 |
| WO2022002153A1 (zh) * | 2020-06-30 | 2022-01-06 | 正大天晴药业集团股份有限公司 | 用于治疗肿瘤的药物 |
-
2022
- 2022-08-05 CN CN202280005896.5A patent/CN116209443A/zh active Pending
- 2022-08-05 JP JP2024504984A patent/JP2024527974A/ja active Pending
- 2022-08-05 EP EP22852342.9A patent/EP4382123A4/en active Pending
- 2022-08-05 US US18/292,655 patent/US20240343807A1/en active Pending
- 2022-08-05 AU AU2022321783A patent/AU2022321783A1/en active Pending
- 2022-08-05 CA CA3227992A patent/CA3227992A1/en active Pending
- 2022-08-05 WO PCT/CN2022/110539 patent/WO2023011631A1/zh not_active Ceased
- 2022-08-05 KR KR1020247006610A patent/KR20240046526A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Levy et al. | Metformin for non-small cell lung cancer patients: Opportunities and pitfalls | |
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| JP2013520442A5 (cg-RX-API-DMAC7.html) | ||
| RU2013126630A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2013542241A5 (cg-RX-API-DMAC7.html) | ||
| JP2020508317A5 (cg-RX-API-DMAC7.html) | ||
| JP2012509889A5 (cg-RX-API-DMAC7.html) | ||
| JP2008503476A5 (cg-RX-API-DMAC7.html) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| JP2011522773A5 (cg-RX-API-DMAC7.html) | ||
| JP2021510725A5 (cg-RX-API-DMAC7.html) | ||
| HRP20160045T1 (hr) | Metoda lijeäśenja raka pomoä†u antagonista dll4 i kemoterapijskog sredstva | |
| JP2011520921A5 (cg-RX-API-DMAC7.html) | ||
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| EP2435041A1 (en) | Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent | |
| EA018447B1 (ru) | Применение комбинации 7-(2,5-дигидро-4-имидазо[1,2-а]пиридин-3-ил-2,5-диоксо-1н-пиррол-3-ил)-9-фтор-1,2,3,4-тетрагидро-2-(1-пиперидинилкарбонил)пирроло[3,2,1-jk][1,4]бензодиазепина с химиотерапевтическим агентом для лечения злокачественных опухолей | |
| JP2022512851A5 (cg-RX-API-DMAC7.html) | ||
| Sprangers et al. | 16 Conventional Chemotherapy | |
| JPWO2022270524A5 (cg-RX-API-DMAC7.html) | ||
| JP2024533067A5 (cg-RX-API-DMAC7.html) | ||
| JP2007277240A5 (cg-RX-API-DMAC7.html) | ||
| Tanaka et al. | Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro | |
| JP2023531090A5 (cg-RX-API-DMAC7.html) |